<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01528046</url>
  </required_header>
  <id_info>
    <org_study_id>MCC-16962</org_study_id>
    <secondary_id>SP003</secondary_id>
    <nct_id>NCT01528046</nct_id>
  </id_info>
  <brief_title>Metformin in Children With Relapsed or Refractory Solid Tumors</brief_title>
  <official_title>A Phase I Trial of Dose Escalation of Metformin in Combination With Vincristine, Irinotecan, and Temozolomide in Children With Relapsed or Refractory Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lee Moffitt Cancer Center and Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pediatric Cancer Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>H. Lee Moffitt Cancer Center and Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the tolerability and safety of escalating doses of&#xD;
      metformin on a backbone of vincristine, irinotecan and temozolomide (VIT) in children with&#xD;
      recurrent and refractory solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Metformin is an oral anti-diabetes medication that activates AMP-activated protein kinase&#xD;
      (AMPK). Recent data from in vitro and in vivo experiments, as well as epidemiologic&#xD;
      retrospective analyses, suggest that metformin has anti-cancer activity. Vincristine,&#xD;
      irinotecan, and temozolomide (VIT) is a combination of chemotherapeutic agents that have&#xD;
      different mechanisms of action as well as disparate side effect profiles. Two recent phase 1&#xD;
      trials have demonstrated that this regimen is safe and well-tolerated in children with&#xD;
      relapsed and refractory solid tumors.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 24, 2012</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Actual">September 26, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD)</measure>
    <time_frame>Average of 3 Months</time_frame>
    <description>To determine the maximum tolerated dose (MTD) of metformin when given in conjunction with VIT in children with refractory and relapsed solid tumors.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Antitumor Activity</measure>
    <time_frame>Average of 3 Months</time_frame>
    <description>To evaluate the antitumor activity of the addition of metformin to VIT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>Average of 3 Months</time_frame>
    <description>To describe the pharmacokinetics of metformin in children with relapsed malignancies receiving VIT combination chemotherapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics</measure>
    <time_frame>Average of 3 Months</time_frame>
    <description>To define the pharmacodynamics of metformin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metformin Concentrations</measure>
    <time_frame>Average of 3 Months</time_frame>
    <description>To determine tissue and tumor metformin concentrations in patients undergoing resection.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Solid Tumors</condition>
  <condition>Primary Brain Tumors</condition>
  <arm_group>
    <arm_group_label>Metformin in Combination with VIT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive metformin in combination with vincristine, irinotecan and temozolomide (VIT).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine</intervention_name>
    <description>Vincristine (VCR) = 1.5 mg/m^2/day (maximum dose 2 mg), days 1 and 8, administered as intravenous (IV) bolus over 1-5 minutes</description>
    <arm_group_label>Metformin in Combination with VIT</arm_group_label>
    <other_name>VCR</other_name>
    <other_name>Oncovin</other_name>
    <other_name>NSC #067574</other_name>
    <other_name>Vincristine sulfate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <description>Irinotecan (IRN) = 50 mg/m^2/day, days 1-5, IV over 60 minutes</description>
    <arm_group_label>Metformin in Combination with VIT</arm_group_label>
    <other_name>CPT-11</other_name>
    <other_name>Camptothecin-11</other_name>
    <other_name>Camptosar ®</other_name>
    <other_name>NSC#616348</other_name>
    <other_name>IRN</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide</intervention_name>
    <description>Temozolomide (TEM) = 50 mg/m^2/day by mouth (PO) Days 1-5</description>
    <arm_group_label>Metformin in Combination with VIT</arm_group_label>
    <other_name>Temodar™</other_name>
    <other_name>NSC #362856</other_name>
    <other_name>TEM</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Metformin (MET) = dose as per dose escalation, divided twice a day (BID), PO continuously for the 21 day cycle.</description>
    <arm_group_label>Metformin in Combination with VIT</arm_group_label>
    <other_name>Glucophage ®</other_name>
    <other_name>MET</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age: Patients must be &gt; 1 year of age and ≤ 18 years of age at time of initiation of&#xD;
             protocol therapy.&#xD;
&#xD;
          -  Diagnosis: Patients have a histologically or radiographically confirmed relapsed or&#xD;
             refractory solid tumor or primary central nervous system (CNS) malignancy.&#xD;
&#xD;
          -  Disease Status: Patients must have radiographically measurable disease.&#xD;
&#xD;
          -  Therapeutic Options: Patients must have relapsed or refractory cancers for which there&#xD;
             is no known curative option or other available therapy proven to prolong survival with&#xD;
             an acceptable quality of life.&#xD;
&#xD;
          -  Performance Level: Karnofsky ≥ 50% for patients older than 16 years old, and Lansky ≥&#xD;
             50 for patients 1-16 years old.&#xD;
&#xD;
          -  Prior Therapy: Patients may have received prior therapy including vincristine,&#xD;
             irinotecan, or temozolomide. Patients may not have previously been treated with&#xD;
             combination therapy of irinotecan and temozolomide.&#xD;
&#xD;
          -  Patients must be fully recovered from the acute toxic effects of all prior&#xD;
             chemotherapy, immunotherapy, or radiotherapy prior to entering this study.&#xD;
&#xD;
               -  Myelosuppressive chemotherapy: Patients must not have received myelosuppressive&#xD;
                  chemotherapy within 3 weeks of starting protocol therapy, or a minimum of six&#xD;
                  weeks must have elapsed since prior nitrosurea chemotherapy.&#xD;
&#xD;
               -  Hematopoietic growth factor: At least 7 days must have elapsed since the last&#xD;
                  administration of filgrastim, or 14 days since administration of pegfilgrastim.&#xD;
&#xD;
               -  Biologic (anti-neoplastic agent): At least 7 must have elapsed since the last&#xD;
                  administration of any biologic agent.&#xD;
&#xD;
               -  Radiation therapy (XRT): At least 14 days since the last dose of local palliative&#xD;
                  radiation therapy. Greater than 6 months must have elapsed since the last day of&#xD;
                  treatment if given total body irradiation, craniospinal irradiation.&#xD;
&#xD;
               -  Autologous or Allogenic Stem Cell Transplant: Complete resolution of graft versus&#xD;
                  host disease and no current need for immunosuppressive medication. Greater than 3&#xD;
                  months must have elapsed since engraftment and no longer requiring transfusion of&#xD;
                  platelets or injection of colony stimulating factors.&#xD;
&#xD;
          -  Organ Function Requirements&#xD;
&#xD;
               -  Bone Marrow Function: Peripheral absolute neutrophil count (ANC) ≥ 1000/μL;&#xD;
                  Platelet count ≥ 100,000/μL (no platelet transfusion within 7 days prior to&#xD;
                  obtaining laboratory result); Hemoglobin ≥ 8.0 gm/dL&#xD;
&#xD;
               -  Adequate Renal Function: Creatinine clearance or glomerular filtration rate ≥&#xD;
                  70ml/min/1.73m^2&#xD;
&#xD;
               -  Adequate Liver Function: Total bilirubin ≤ 1.5x upper limit of normal (ULN) for&#xD;
                  age; alanine transaminase (ALT) ≤ 5x ULN; Serum albumin ≥ 2gm/dL&#xD;
&#xD;
          -  Informed Consent: All patients ≥ 18 years of age must sign a written informed consent.&#xD;
             For patients &lt; 18 years old, the patient's parents or legal guardians must sign a&#xD;
             written informed consent, unless the patient is an emancipated minor. Childhood&#xD;
             Assent, when age appropriate as per institutional guidelines, should be signed by the&#xD;
             participating patient.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Significant organ dysfunction, not meeting inclusion criteria.&#xD;
&#xD;
          -  Pregnancy or Breast-Feeding woman will not be entered on this study due to risks of&#xD;
             fetal and teratogenic adverse events as seen in animal/human studies.&#xD;
&#xD;
          -  Concomitant Medications:&#xD;
&#xD;
               -  Growth factor: Growth factors that support platelet or white cell number of&#xD;
                  function must not have been administered within the past 7 days.&#xD;
&#xD;
               -  Steroids: Patients with CNS tumors who have not been on a stable or decreasing&#xD;
                  dose of dexamethasone for the past 7 days.&#xD;
&#xD;
               -  Investigational Drugs: Patients who are currently receiving another&#xD;
                  investigational drug.&#xD;
&#xD;
               -  Anti-cancer Agents: Patients who are currently receiving other anti-cancer&#xD;
                  agents.&#xD;
&#xD;
               -  Medication Allergy: Allergy or intolerance to agents on this protocol:&#xD;
                  vincristine, irinotecan, temozolomide, or metformin; Allergy to cephalosporins.&#xD;
&#xD;
               -  Infection: Patients who have uncontrolled infection, positive blood cultures&#xD;
                  within the past 48 hours, or receiving treatment for Clostridium difficile&#xD;
                  infection.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan Gill, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>The Children's Hospital at Montefiore, Pediatric Cancer Foundation, Sunshine Project</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Damon Reed, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>H. Lee Moffitt Cancer Center and Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Connecticut Children's Medical Center</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemours/Alfred I. duPont Hospital for Children, Delaware</name>
      <address>
        <city>Wilmington</city>
        <state>Delaware</state>
        <zip>19803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemours Children's Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami Sylvester Comprehensive Cancer Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins All Children's Hospital</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampa General Hospital</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center and Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Sidney Kimmel Comprehensive Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital at Montefiore</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Primary Children's Medical Center/Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84113</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.moffitt.org/research--clinical-trials/clinical-trials</url>
    <description>Moffitt Cancer Center Clinical Trials website</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>February 3, 2012</study_first_submitted>
  <study_first_submitted_qc>February 6, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 7, 2012</study_first_posted>
  <last_update_submitted>October 7, 2021</last_update_submitted>
  <last_update_submitted_qc>October 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>central nervous system (CNS)</keyword>
  <keyword>malignancy</keyword>
  <keyword>relapsed</keyword>
  <keyword>refractory</keyword>
  <keyword>pediatric</keyword>
  <keyword>recurrent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Camptothecin</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Temozolomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

